Pfizer (PFE) Receives "Underperform" Rating from RBC Capital | P

RBC Capital has initiated coverage on Pfizer (PFE) with an “Underperform” rating and set a price target of $25.00 USD. This comes amidst a series of recent analyst rating

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin